Health Trials

A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies

ConditionsLymphoma, B CellLymphoma Non-HodgkinHigh Grade B Cell LymphomaRichter Transformation LymphomaGrade 3b Follicular LymphomaPrimary Mediastinal B Cell LymphomaDiffuse Large B Cell Lymphoma (DLBCL)
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorUmoja Biopharma

About this trial

This study is a Phase 1/2 dose-finding and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV400. The study will enroll patients with relapsed/refractory B-cell malignancies, including large B-cell lymphoma (LBCL).

Eligibility criteria

Qualifiers

18 years or older

Provides voluntary written informed consent

Relapsed or refractory large B-cell lymphoma (LBCL)

Measurable disease according to Lugano 2014 criteria

Disqualifiers

Women who are pregnant or breastfeeding

Current isolated central nervous system (CNS) involvement

Prior allogeneic bone marrow transplant, gene therapy, or adoptive cell transfer (except tumor-infiltrating lymphocytes, CAR-NK cells, T-cell receptor [TCR] fusion constructs, TCR T cells, and CAR T cells)

History of or active human immunodeficiency virus (HIV)

Trial design

Treatments tested in this trial

  • UB-VV400
  • Rapamycin (sirolimus)

Treatment groups

274 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Umoja Biopharma

Lead sponsor

Source ClinicalTrials.gov